Literature DB >> 19697442

Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future.

Aviram Nissan1, Alexander Stojadinovic, Alfredo Garofalo, Jesus Esquivel, Pompiliu Piso.   

Abstract

The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19697442     DOI: 10.1002/jso.21323

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Impact of Previous Gynecologic Surgical Procedures on Outcomes of Non-Gynecologic Peritoneal Malignancies Mimicking Ovarian Cancer: Less Is More?

Authors:  Marcello Guaglio; Dario Baratti; Shigeki Kusamura; Arthur C V Reis; Matteo Montenovo; Valentina Bartolini; Luigi Battaglia; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2021-02-27       Impact factor: 5.344

2.  Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.

Authors:  Eun Jung Cho; Bo Sun; Kyung-Oh Doh; Erin M Wilson; Sandra Torregrosa-Allen; Bennett D Elzey; Yoon Yeo
Journal:  Biomaterials       Date:  2014-10-24       Impact factor: 12.479

Review 3.  Drug delivery systems for intraperitoneal therapy.

Authors:  Gaurav Bajaj; Yoon Yeo
Journal:  Pharm Res       Date:  2010-03-03       Impact factor: 4.200

4.  Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.

Authors:  Gaurav Bajaj; Mi Ran Kim; Sulma I Mohammed; Yoon Yeo
Journal:  J Control Release       Date:  2011-12-09       Impact factor: 9.776

Review 5.  Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.

Authors:  Paul H Sugarbaker; Kurt Van der Speeten
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 6.  Multimodality treatment strategies have changed prognosis of peritoneal metastases.

Authors:  Corneliu Lungoci; Aurel Ion Mironiuc; Valentin Muntean; Traian Oniu; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

7.  Nanocrystals for the parenteral delivery of poorly water-soluble drugs.

Authors:  Bo Sun; Yoon Yeo
Journal:  Curr Opin Solid State Mater Sci       Date:  2012-12-01       Impact factor: 11.354

8.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.

Authors:  Xiao-Jun Yang; Chao-Qun Huang; Tao Suo; Lie-Jun Mei; Guo-Liang Yang; Fu-Lin Cheng; Yun-Feng Zhou; Bin Xiong; Yutaka Yonemura; Yan Li
Journal:  Ann Surg Oncol       Date:  2011-03-23       Impact factor: 5.344

9.  Specific extracellular matrix remodeling signature of colon hepatic metastases.

Authors:  Maguy Del Rio; Caroline Mollevi; Nadia Vezzio-Vie; Frédéric Bibeau; Marc Ychou; Pierre Martineau
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

10.  Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer.

Authors:  Hai-Bin Cui; Huai-E Ge; Xi-Yong Bai; Wei Zhang; Yuan-Yuan Zhang; Juan Wang; Xing Li; Lian-Ping Xing; Sheng-Hu Guo; Zhi-Yu Wang
Journal:  Exp Ther Med       Date:  2014-03-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.